{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:07:16Z","timestamp":1787504836962,"version":"build-2736575974"},"reference-count":209,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1160"],"award-info":[{"award-number":["SFB1160"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC 2189 Project ID: 390939984"],"award-info":[{"award-number":["EXC 2189 Project ID: 390939984"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR167"],"award-info":[{"award-number":["TRR167"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["Proposal n 681012 GvHDCure"],"award-info":[{"award-number":["Proposal n 681012 GvHDCure"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Myeloproliferative diseases, including myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS), are driven by genetic abnormalities and increased inflammatory signaling and are at high risk to transform into acute myeloid leukemia (AML). Myeloid-derived suppressor cells were reported to enhance leukemia immune escape by suppressing an effective anti-tumor immune response. MPNs are a potentially immunogenic disease as shown by their response to interferon-\u03b1 treatment and allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Novel immunotherapeutic approaches such as immune checkpoint inhibition, tumor vaccination, or cellular therapies using target-specific lymphocytes have so far not shown strong therapeutic efficacy. Potential reasons could be the pro-inflammatory and immunosuppressive microenvironment in the bone marrow of patients with MPN, driving tumor immune escape. In this review, we discuss the biology of MPNs with respect to the pro-inflammatory milieu in the bone marrow (BM) and potential immunotherapeutic approaches.<\/jats:p>","DOI":"10.3390\/cells9061559","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T09:36:04Z","timestamp":1593509764000},"page":"1559","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Immunotherapy in Myeloproliferative Diseases"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0770-4994","authenticated-orcid":false,"given":"Lukas M.","family":"Braun","sequence":"first","affiliation":[{"name":"Department of Medicine I, Medical Center\u2014University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"},{"name":"Faculty of Biology, University of Freiburg, 79104 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6565-3393","authenticated-orcid":false,"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Medical Center\u2014University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"},{"name":"German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"},{"name":"Comprehensive Cancer Center Freiburg (CCCF), University of Freiburg, 79106 Freiburg, Germany"},{"name":"Centre for Biological Signalling Studies (BIOSS) and Centre for Integrative Biological Signalling Studies (CIBSS), University of Freiburg, 79104 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders","volume":"355","author":"Campbell","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 who classification and diagnostic criteria for myeloproliferative neoplasms: Document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_4","first-page":"895","article-title":"Myeloproliferative neoplasms","volume":"377","author":"Spivak","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.3389\/fimmu.2018.02264","article-title":"Novel strategies for peptide-based vaccines in hematological malignancies","volume":"9","author":"Klausen","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal jak2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of jak2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase jak2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase jak2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"Jak2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"Mpl515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Pikman, Y., Lee, B.H., Mercher, T., McDowell, E., Ebert, B.L., Gozo, M., Cuker, A., Wernig, G., Moore, S., and Galinsky, I. (2006). Mplw515l is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med., 3.","DOI":"10.1371\/journal.pmed.0030270"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2007-05-089003","article-title":"Evidence for mpl w515l\/k mutations in hematopoietic stem cells in primitive myelofibrosis","volume":"110","author":"Chaligne","year":"2007","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"Mpl mutations in myeloproliferative disorders: Analysis of the pt-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in calr-mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic calr mutations in myeloproliferative neoplasms with nonmutated jak2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s11899-018-0491-5","article-title":"Leukemic transformation of myeloproliferative neoplasms: Therapeutic and genomic considerations","volume":"13","author":"Li","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.seminhematol.2004.02.011","article-title":"The chronic myeloproliferative disorders: Clonality and clinical heterogeneity","volume":"41","author":"Spivak","year":"2004","journal-title":"Semin. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000204873","article-title":"Acute transformation in nonleukemic chronic myeloproliferative disorders: Actuarial probability and main characteristics in a series of 218 patients","volume":"85","author":"Cervantes","year":"1991","journal-title":"Acta Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1182\/blood-2012-10-464248","article-title":"Treatment outcomes following leukemic transformation in philadelphia-negative myeloproliferative neoplasms","volume":"121","author":"Kennedy","year":"2013","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases","volume":"105","author":"Mesa","year":"2005","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","article-title":"Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias","volume":"70","author":"Manshouri","year":"2010","journal-title":"Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2009-07-235119","article-title":"Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of philadelphia chromosome-negative myeloproliferative neoplasms","volume":"115","author":"Thoennissen","year":"2010","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","article-title":"Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent srsf2 mutations that are associated with adverse outcome","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a jak2 mutation-positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMc1012718","article-title":"P53 lesions in leukemic transformation","volume":"364","author":"Harutyunyan","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/leu.2014.7","article-title":"Whole-exome sequencing of polycythemia vera revealed novel driver genes and somatic mutation shared by t cells and granulocytes","volume":"28","author":"Wang","year":"2014","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjh.14269","article-title":"Application of an ngs-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera","volume":"175","author":"Delic","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2012-05-429696","article-title":"Srsf2 mutations in primary myelofibrosis: Significant clustering with idh mutations and independent association with inferior overall and leukemia-free survival","volume":"120","author":"Lasho","year":"2012","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.3324\/haematol.2016.152363","article-title":"Genomic analysis of myeloproliferative neoplasms in chronic and acute phases","volume":"102","author":"Courtier","year":"2017","journal-title":"Haematologica"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/leu.2013.102","article-title":"A role for reactive oxygen species in jak2 v617f myeloproliferative neoplasm progression","volume":"27","author":"Marty","year":"2013","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Hasselbalch, H.C., Thomassen, M., Riley, C.H., Kjaer, L., Larsen, T.S., Jensen, M.K., Bjerrum, O.W., Kruse, T.A., and Skov, V. (2014). Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of nrf2 for genomic instability and disease progression. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0112786"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2016-07-730556","article-title":"The nlrp3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype","volume":"128","author":"Basiorka","year":"2016","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/s41467-020-15497-1","article-title":"Oncogenic kras(g12d) causes myeloproliferation via nlrp3 inflammasome activation","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"Jak-stat pathway activation in malignant and nonmalignant cells contributes to mpn pathogenesis and therapeutic response","volume":"5","author":"Kleppe","year":"2015","journal-title":"Cancer Discov"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/onc.2010.479","article-title":"Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in polycythemia vera and contribute to the growth of clonal erythroblasts independently of jak2v617f","volume":"30","author":"Boissinot","year":"2011","journal-title":"Oncogene"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.stem.2018.10.013","article-title":"Inhibition of inflammatory signaling in tet2 mutant preleukemic cells mitigates stress-induced abnormalities and clonal hematopoiesis","volume":"23","author":"Cai","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with tet2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3389\/fonc.2017.00265","article-title":"Inflammatory signaling pathways in preleukemic and leukemic stem cells","volume":"7","author":"Hemmati","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"E1490","DOI":"10.1073\/pnas.1616420114","article-title":"Dnmt3a restrains mast cell inflammatory responses","volume":"114","author":"Leoni","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1182\/blood-2015-11-679431","article-title":"Loss of ezh2 cooperates with jak2v617f in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm","volume":"127","author":"Yang","year":"2016","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1182\/blood-2018-04-846220","article-title":"Jak2v617f and dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation","volume":"132","author":"Jacquelin","year":"2018","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11899-019-00527-7","article-title":"The rationale for immunotherapy in myeloproliferative neoplasms","volume":"14","author":"Masarova","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1182\/blood.V88.12.4534.bloodjournal88124534","article-title":"Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in cd34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia","volume":"88","author":"Chevillard","year":"1996","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2353\/ajpath.2008.071030","article-title":"Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines","volume":"172","author":"Bock","year":"2008","journal-title":"Am. J. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2008-06-158386","article-title":"Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence","volume":"112","author":"Lataillade","year":"2008","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.yexcr.2008.11.020","article-title":"Hypoxia regulates inflammatory gene expression in endothelial cells","volume":"315","author":"Flamant","year":"2009","journal-title":"Exp. Cell Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"Stats: Transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bcmd.2012.11.009","article-title":"Microrna deregulation in polycythemia vera and essential thrombocythemia patients","volume":"50","author":"Zhan","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.1991.tb07952.x","article-title":"Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia","volume":"77","author":"Martyre","year":"1991","journal-title":"Br. J. Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1006\/cyto.2002.1994","article-title":"Abnormal production of interleukin (il)-11 and il-8 in polycythaemia vera","volume":"20","author":"Hermouet","year":"2002","journal-title":"Cytokine"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2141.2005.05674.x","article-title":"Serum interleukin (il)-1, il-2, sil-2ra, il-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases","volume":"130","author":"Panteli","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1177\/030089160909500326","article-title":"Evaluation of interleukin-17 serum levels in patients with chronic myeloproliferative diseases","volume":"95","author":"Allegra","year":"2009","journal-title":"Tumori"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1479-5876-7-39","article-title":"Gene and microrna analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: Down-regulation of micro rna-1 and -133a","volume":"7","author":"Slezak","year":"2009","journal-title":"J. Transl. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of incb018424, a jak1 and jak2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"101987","DOI":"10.1155\/2015\/101987","article-title":"The hen or the egg: Inflammatory aspects of murine mpn models","volume":"2015","author":"Jutzi","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1073\/pnas.1812266115","article-title":"Blocking il-1beta reverses the immunosuppression in mouse breast cancer and synergizes with anti-pd-1 for tumor abrogation","volume":"116","author":"Kaplanov","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/cas.13433","article-title":"Immune-suppressive effects of interleukin-6 on t-cell-mediated anti-tumor immunity","volume":"109","author":"Tsukamoto","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ccr.2011.03.009","article-title":"Stat3\/socs3 activation by il-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer","volume":"19","author":"Lesina","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1158\/0008-5472.CAN-12-2353","article-title":"Critical role of stat3 in il-6-mediated drug resistance in human neuroblastoma","volume":"73","author":"Ara","year":"2013","journal-title":"Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cell.2009.12.052","article-title":"Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing il-6 and tnf expression","volume":"140","author":"Park","year":"2010","journal-title":"Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: Impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1158\/0008-5472.CAN-16-2446","article-title":"Soluble il6r expressed by myeloid cells reduces tumor-specific th1 differentiation and drives tumor progression","volume":"77","author":"Tsukamoto","year":"2017","journal-title":"Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.1038\/ncomms7702","article-title":"Il-6-mediated environmental conditioning of defective th1 differentiation dampens antitumour immune responses in old age","volume":"6","author":"Tsukamoto","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1158\/2326-6066.CIR-16-0073","article-title":"Myeloid stat3 promotes lung tumorigenesis by transforming tumor immunosurveillance into tumor-promoting inflammation","volume":"5","author":"Zhou","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"812","DOI":"10.4049\/jimmunol.1103797","article-title":"The key role of il-6-arginase cascade for inducing dendritic cell-dependent cd4(+) t cell dysfunction in tumor-bearing mice","volume":"190","author":"Narita","year":"2013","journal-title":"J. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.immuni.2005.09.010","article-title":"Il-6-stat3 controls intracellular mhc class ii alphabeta dimer level through cathepsin s activity in dendritic cells","volume":"23","author":"Kitamura","year":"2005","journal-title":"Immunity"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1182\/blood-2003-06-1856","article-title":"Allogeneic hematopoietic stem cell transplantation for myelofibrosis","volume":"102","author":"Deeg","year":"2003","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.hoc.2014.08.003","article-title":"Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease","volume":"28","author":"Salit","year":"2014","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/j.bbmt.2016.08.029","article-title":"Outcome of allogeneic hematopoietic stem cell transplantation for patients with chronic and advanced phase myelofibrosis","volume":"22","author":"Keyzner","year":"2016","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/sj.bmt.1702568","article-title":"Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: Demonstration of a graft-versus-myelofibrosis effect","volume":"26","author":"Cervantes","year":"2000","journal-title":"Bone Marrow Transpl."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/sj.bmt.1704657","article-title":"Outcome of allogeneic stem cell transplantation in patients with myelofibrosis","volume":"34","author":"Ditschkowski","year":"2004","journal-title":"Bone Marrow Transpl."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1046\/j.1365-2141.1997.3083125.x","article-title":"Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis","volume":"98","author":"Anderson","year":"1997","journal-title":"Br. J. Haematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","article-title":"Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis","volume":"125","author":"Kroger","year":"2015","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood.V67.6.1693.1693","article-title":"Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation","volume":"67","author":"Rajantie","year":"1986","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.hoc.2010.02.003","article-title":"Hematopoietic stem cell transplantation for mds","volume":"24","author":"Bartenstein","year":"2010","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.leukres.2008.12.019","article-title":"Impact on survival of different treatments for myelodysplastic syndromes (mds)","volume":"33","author":"Nachtkamp","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2003-11-3750","article-title":"Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation","volume":"104","author":"Anagnostopoulos","year":"2004","journal-title":"Blood"},{"key":"ref_88","first-page":"1997","article-title":"Bone marrow transplantation from hla-identical siblings as treatment for myelodysplasia","volume":"100","author":"Sierra","year":"2002","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood-2011-08-372904","article-title":"The dynamic international prognostic scoring system for myelofibrosis predicts outcomes after hematopoietic cell transplantation","volume":"119","author":"Scott","year":"2012","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2141.2011.09009.x","article-title":"Risk models predicting survival after reduced-intensity transplantation for myelofibrosis","volume":"157","author":"Alchalby","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s11912-013-0340-6","article-title":"Hematopoietic stem cell transplantation for acute myeloid leukemia: To whom, when, and how","volume":"15","author":"Magenau","year":"2013","journal-title":"Curr. Oncol. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2011-08-375840","article-title":"Treatment, risk factors, and outcome of adults with relapsed aml after reduced intensity conditioning for allogeneic stem cell transplantation","volume":"119","author":"Schmid","year":"2012","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2009-12-257253","article-title":"In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia","volume":"116","author":"Choi","year":"2010","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory t cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (aml)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term outcomes of 107 patients with myelofibrosis receiving jak1\/jak2 inhibitor ruxolitinib: Survival advantage in comparison to matched historical controls","volume":"120","author":"Verstovsek","year":"2012","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/bmt.2013.173","article-title":"Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the jak1 and jak2 inhibitor ruxolitinib","volume":"49","author":"Jaekel","year":"2014","journal-title":"Bone Marrow Transpl."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3324\/haematol.2018.206151","article-title":"State-of-the-art review: Allogeneic stem cell transplantation for myelofibrosis in 2019","volume":"104","author":"McLornan","year":"2019","journal-title":"Haematologica"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.leukres.2016.02.004","article-title":"Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm","volume":"43","author":"Wang","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e954829","DOI":"10.4161\/21624011.2014.954829","article-title":"Myeloid derived suppressor cells-an overview of combat strategies to increase immunotherapy efficacy","volume":"4","author":"Draghiciu","year":"2015","journal-title":"OncoImmunology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4049\/jimmunol.172.2.989","article-title":"Antigen-specific inhibition of cd8+ t cell response by immature myeloid cells in cancer is mediated by reactive oxygen species","volume":"172","author":"Kusmartsev","year":"2004","journal-title":"J. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.4049\/jimmunol.175.7.4583","article-title":"Tumor-associated cd8+ t cell tolerance induced by bone marrow-derived immature myeloid cells","volume":"175","author":"Kusmartsev","year":"2005","journal-title":"J. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1158\/0008-5472.CAN-05-1299","article-title":"Gr-1+cd115+ immature myeloid suppressor cells mediate the development of tumor-induced t regulatory cells and t-cell anergy in tumor-bearing host","volume":"66","author":"Huang","year":"2006","journal-title":"Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2174\/1381612043452893","article-title":"Inhibition of mhc ii gene transcription by nitric oxide and antioxidants","volume":"10","author":"Harari","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1172\/JCI20225","article-title":"Inducible nitric oxide synthase in t cells regulates t cell death and immune memory","volume":"113","author":"Vig","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1084\/jem.20050715","article-title":"Arginase i in myeloid suppressor cells is induced by cox-2 in lung carcinoma","volume":"202","author":"Rodriguez","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2006-06-031856","article-title":"L-arginine availability regulates t-lymphocyte cell-cycle progression","volume":"109","author":"Rodriguez","year":"2007","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Modolell, M., Choi, B.S., Ryan, R.O., Hancock, M., Titus, R.G., Abebe, T., Hailu, A., Muller, I., Rogers, M.E., and Bangham, C.R. (2009). Local suppression of t cell responses by arginase-induced l-arginine depletion in nonhealing leishmaniasis. PLoS Negl. Trop. Dis., 3.","DOI":"10.1371\/journal.pntd.0000480"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40425-017-0308-4","article-title":"Inhibition of arginase by cb-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment","volume":"5","author":"Steggerda","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1172\/JCI67580","article-title":"Induction of myelodysplasia by myeloid-derived suppressor cells","volume":"123","author":"Chen","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11899-014-0227-0","article-title":"An immune dysregulation in mpn","volume":"9","author":"Barosi","year":"2014","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00432-017-2394-6","article-title":"Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells","volume":"143","author":"Zhou","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Bose, P., Verstovsek, S., Cortes, J.E., Tse, S., Gasior, Y., Jain, N., Jabbour, E.J., Estrov, Z., Alvarado, Y., and DiNardo, C.D. (2020). A phase 1\/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia.","DOI":"10.1038\/s41375-020-0778-0"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/leu.2016.260","article-title":"Bet protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary aml cells","volume":"31","author":"Saenz","year":"2017","journal-title":"Leukemia"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF00320230","article-title":"Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a","volume":"58","author":"Tichelli","year":"1989","journal-title":"Blut"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","article-title":"Depletion of jak2v617f myeloproliferative neoplasm-propagating stem cells by interferon-alpha in a murine model of polycythemia vera","volume":"121","author":"Mullally","year":"2013","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3324\/haematol.2011.061390","article-title":"Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients","volume":"97","author":"Gowin","year":"2012","journal-title":"Haematologica"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/ejh.12687","article-title":"Interferon-alpha induces marked alterations in circulating regulatory t cells, nk cell subsets, and dendritic cells in patients with jak2v617f-positive essential thrombocythemia and polycythemia vera","volume":"97","author":"Riley","year":"2016","journal-title":"Eur J. Haematol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a","volume":"108","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3324\/haematol.2017.181297","article-title":"Benefits and pitfalls of pegylated interferon-alpha2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: A french intergroup of myeloproliferative neoplasms (fim) study","volume":"103","author":"Ianotto","year":"2018","journal-title":"Haematologica"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1196\/annals.1415.030","article-title":"Ifn-alpha and novel strategies of combination therapy for cancer","volume":"1112","author":"Bracci","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cytogfr.2006.07.001","article-title":"Interferon: The pathways of discovery i. Molecular and cellular aspects","volume":"17","author":"Billiau","year":"2006","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood.V96.13.4313","article-title":"Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells","volume":"96","author":"Xu","year":"2000","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/ejh.12420","article-title":"Expansion of circulating cd56bright natural killer cells in patients with jak2-positive chronic myeloproliferative neoplasms during treatment with interferon-alpha","volume":"94","author":"Riley","year":"2015","journal-title":"Eur J. Haematol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/onc.2011.221","article-title":"Inflammatory signaling compromises cell responses to interferon alpha","volume":"31","author":"Huangfu","year":"2012","journal-title":"Oncogene"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jhep.2006.01.037","article-title":"Oxidative stress inhibits ifn-alpha-induced antiviral gene expression by blocking the jak-stat pathway","volume":"45","author":"Cippitelli","year":"2006","journal-title":"J. Hepatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cytogfr.2013.01.004","article-title":"The role of cytokines in the initiation and progression of myelofibrosis","volume":"24","author":"Hasselbalch","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-018-0700-2","article-title":"Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: Minimal residual disease and cure?","volume":"41","author":"Hasselbalch","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_131","first-page":"73","article-title":"Combination therapy with interferon and jak1-2 inhibitor is feasible: Proof of concept with rapid reduction in jak2v617f-allele burden in polycythemia vera","volume":"3","author":"Bjorn","year":"2014","journal-title":"Leuk Res. Rep."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1002\/cam4.1619","article-title":"Safety and efficacy of combination therapy of interferon-alpha2 and ruxolitinib in polycythemia vera and myelofibrosis","volume":"7","author":"Mikkelsen","year":"2018","journal-title":"Cancer Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s11899-017-0403-0","article-title":"Novel therapies for myelofibrosis","volume":"12","author":"Pettit","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-018-0585-5","article-title":"Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis","volume":"11","author":"Kvasnicka","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00277-017-2994-x","article-title":"Ruxolitinib reduces jak2 p.V617f allele burden in patients with polycythemia vera enrolled in the response study","volume":"96","author":"Vannucchi","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","article-title":"The effect of long-term ruxolitinib treatment on jak2p.V617f allele burden in patients with myelofibrosis","volume":"126","author":"Deininger","year":"2015","journal-title":"Blood"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Greenfield, G., McPherson, S., Mills, K., and McMullin, M.F. (2018). The ruxolitinib effect: Understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms. J. Transl. Med., 16.","DOI":"10.1186\/s12967-018-1729-7"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ccr3.281","article-title":"The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms","volume":"3","author":"Bjorn","year":"2015","journal-title":"Clin. Case Rep."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","article-title":"The jak-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/leu.2016.155","article-title":"The jak inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of rock","volume":"30","author":"Rudolph","year":"2016","journal-title":"Leukemia"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-14-3198","article-title":"Jak inhibition impairs nk cell function in myeloproliferative neoplasms","volume":"75","author":"Schonberg","year":"2015","journal-title":"Cancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjh.13373","article-title":"Jak1\/2 inhibition impairs t cell function in vitro and in patients with myeloproliferative neoplasms","volume":"169","author":"Stubig","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/leu.2013.296","article-title":"Rapid and long-lasting decrease of t-regulatory cells in patients with myelofibrosis treated with ruxolitinib","volume":"28","author":"Massa","year":"2014","journal-title":"Leukemia"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1378\/chest.12-1604","article-title":"An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor","volume":"143","author":"Wysham","year":"2013","journal-title":"Chest"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/leu.2013.235","article-title":"Reactivation of hepatitis b virus infection following ruxolitinib treatment in a patient with myelofibrosis","volume":"28","author":"Caocci","year":"2014","journal-title":"Leukemia"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMc1302135","article-title":"Progressive multifocal leukoencephalopathy associated with ruxolitinib","volume":"369","author":"Wathes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Testa, U., Pelosi, E., and Castelli, G. (2019). Cd123 as a therapeutic target in the treatment of hematological malignancies. Cancers, 11.","DOI":"10.3390\/cancers11091358"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Lasho, T., Finke, C., Kimlinger, T.K., Zblewski, D., Chen, D., Patnaik, M.M., Hanson, C.A., Brooks, C., Tefferi, A., and Pardanani, A. (2014). Expression of cd123 (il-3r-alpha), a therapeutic target of sl-401, on myeloproliferative neoplasms. Blood, 124.","DOI":"10.1182\/blood.V124.21.5577.5577"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1600-065X.2012.01164.x","article-title":"The gm-csf\/il-3\/il-5 cytokine receptor family: From ligand recognition to initiation of signaling","volume":"250","author":"Broughton","year":"2012","journal-title":"Immunol. Rev."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2050-7771-2-4","article-title":"Cd 123 is a membrane biomarker and a therapeutic target in hematologic malignancies","volume":"2","author":"Testa","year":"2014","journal-title":"Biomark. Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2019-131217","article-title":"Results from a phase 1\/2 clinical trial of tagraxofusp (sl-401) in patients with intermediate, or high risk, relapsed\/refractory myelofibrosis","volume":"134","author":"Pemmaraju","year":"2019","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2002-03-0852","article-title":"Elevated expression of il-3ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis","volume":"100","author":"Testa","year":"2002","journal-title":"Blood"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Alkharabsheh, O., and Frankel, A.E. (2019). Clinical activity and tolerability of sl-401 (tagraxofusp): Recombinant diphtheria toxin and interleukin-3 in hematologic malignancies. Biomedicines, 7.","DOI":"10.3390\/biomedicines7010006"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/sj.leu.2401357","article-title":"Dt388-gm-csf, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a Sci.d mouse model of acute myeloid leukemia","volume":"13","author":"Hall","year":"1999","journal-title":"Leukemia"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/10428190701799035","article-title":"Phase i clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia","volume":"49","author":"Frankel","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/sj.leu.2402744","article-title":"Diphtheria toxin-interleukin-3 fusion protein (dt(388)il3) prolongs disease-free survival of leukemic immunocompromised mice","volume":"17","author":"Black","year":"2003","journal-title":"Leukemia"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.stem.2009.04.018","article-title":"Monoclonal antibody-mediated targeting of cd123, il-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells","volume":"5","author":"Jin","year":"2009","journal-title":"Cell Stem Cell"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1182\/blood-2012-12-475194","article-title":"Monoclonal antibody targeting of il-3 receptor alpha with csl362 effectively depletes cml progenitor and stem cells","volume":"123","author":"Nievergall","year":"2014","journal-title":"Blood"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1038\/leu.2014.128","article-title":"Targeting of acute myeloid leukemia in vitro and in vivo with an anti-cd123 mab engineered for optimal adcc","volume":"28","author":"Busfield","year":"2014","journal-title":"Leukemia"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Smith, B.D., Roboz, G.J., Walter, R.B., Altman, J.K., Ferguson, A., Curcio, T.J., Orlowski, K.F., Garrett, L., Busfield, S.J., and Barnden, M. (2014). First-in man, phase 1 study of csl362 (anti-il3r alpha\/anti-cd123 monoclonal antibody) in patients with cd123+acute myeloid leukemia (aml) in cr at high risk for early relapse. Blood, 124.","DOI":"10.1182\/blood.V124.21.120.120"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Smith, B.D., Roberts, A.W., Roboz, G.J., DeWitte, M., Ferguson, A., Garrett, L., Curcio, T., Orlowski, K.F., Dasen, S., and Bensen-Kennedy, D.M. (2015). Minimal residual disease (mrd) as exploratory endpoint in a phase 1 study of the anti-cd123 mab csl362 given as post-remission therapy in adult acute myeloid leukemia (aml). Blood, 126.","DOI":"10.1182\/blood.V126.23.3819.3819"},{"key":"ref_165","first-page":"3819","article-title":"Preclinical evaluation of csl362\/jnj-56022473 in combination with decitabine or azacitidine in in vitro assays","volume":"126","author":"Syed","year":"2015","journal-title":"Blood"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/1535-7163.MCT-17-0742","article-title":"Characterization of sgn-cd123a, a potent cd123-directed antibody-drug conjugate for acute myeloid leukemia","volume":"17","author":"Li","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1182\/blood.V126.23.1349.1349","article-title":"First preclinical report of the efficacy and pd results of khk2823, a non-fucosylated fully human monoclonal antibody against il-3r alpha","volume":"126","author":"Akiyama","year":"2015","journal-title":"Blood"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A cd123-targeting antibody-drug conjugate, imgn632, designed to eradicate aml while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e1433521","DOI":"10.1080\/2162402X.2018.1433521","article-title":"Spontaneous t-cell responses against the immune check point programmed-death-ligand 1 (pd-l1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response","volume":"7","author":"Holmstrom","year":"2018","journal-title":"OncoImmunology"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/leu.2016.290","article-title":"The jak2v617f mutation is a target for specific t-cells in the jak2v617f positive myeloproliferative neoplasms","volume":"31","author":"Ahmad","year":"2017","journal-title":"Leukemia"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/leu.2017.214","article-title":"The calreticulin (calr) exon 9 mutations are promising targets for cancer immune therapy","volume":"32","author":"Martinenaite","year":"2018","journal-title":"Leukemia"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.2019000519","article-title":"Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms","volume":"134","author":"Schischlik","year":"2019","journal-title":"Blood"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e1358334","DOI":"10.1080\/2162402X.2017.1358334","article-title":"The jak2v617f and calr exon 9 mutations are shared immunogenic neoantigens in hematological malignancy","volume":"6","author":"Holmstrom","year":"2017","journal-title":"OncoImmunology"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Pecquet, C., Balligand, T., Chachoua, I., Roy, A., Vertenoeil, G., Colau, D., Fertig, E., Marty, C., Nivarthi, H., and Defour, J.P. (2018). Secreted mutant calreticulins as rogue cytokines trigger thrombopoietin receptor activation specifically in calr mutated cells: Perspectives for mpn therapy. Blood, 132.","DOI":"10.1182\/blood-2018-99-118348"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"e1468957","DOI":"10.1080\/2162402X.2018.1468957","article-title":"Spontaneous t-cell responses against arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation","volume":"7","author":"Jorgensen","year":"2018","journal-title":"OncoImmunology"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1476-5381.2009.00291.x","article-title":"Arginase: An emerging key player in the mammalian immune system","volume":"158","author":"Munder","year":"2009","journal-title":"Br. J. Pharm."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1182\/blood-2004-07-2521","article-title":"Arginase i is constitutively expressed in human granulocytes and participates in fungicidal activity","volume":"105","author":"Munder","year":"2005","journal-title":"Blood"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant pd-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/08820139.2016.1197241","article-title":"Cancer\/testis antigens: Expression, regulation, tumor invasion, and use in immunotherapy of cancers","volume":"45","author":"Salmaninejad","year":"2016","journal-title":"Immunol. Invest."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.leukres.2010.02.004","article-title":"The DNA demethylating agent 5-aza-2\u2019-deoxycytidine induces expression of ny-eso-1 and other cancer\/testis antigens in myeloid leukemia cells","volume":"34","author":"Almstedt","year":"2010","journal-title":"Leuk. Res."},{"key":"ref_181","first-page":"961","article-title":"Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2\u2019-deoxycytidine","volume":"62","author":"Liang","year":"2002","journal-title":"Cancer Res."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1124\/mol.65.1.18","article-title":"Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2\u2019-deoxycytidine","volume":"65","author":"Karpf","year":"2004","journal-title":"Mol. Pharm."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Siebenkas, C., Chiappinelli, K.B., Guzzetta, A.A., Sharma, A., Jeschke, J., Vatapalli, R., Baylin, S.B., and Ahuja, N. (2017). Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0179501"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"12840","DOI":"10.18632\/oncotarget.7326","article-title":"Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy","volume":"7","author":"Srivastava","year":"2016","journal-title":"Oncotarget"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood-2009-11-249474","article-title":"Induction of a cd8+ t-cell response to the mage cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia","volume":"116","author":"Goodyear","year":"2010","journal-title":"Blood"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00262-015-1731-3","article-title":"A phase i trial combining decitabine\/dendritic cell vaccine targeting mage-a1, mage-a3 and ny-eso-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma","volume":"64","author":"Krishnadas","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/bloodadvances.2017014175","article-title":"Phase 2 trial of a multivalent wt1 peptide vaccine (galinpepimut-s) in acute myeloid leukemia","volume":"2","author":"Maslak","year":"2018","journal-title":"Blood Adv."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of pd-l1, pd-l2, pd-1 and ctla4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"9612","DOI":"10.18632\/oncotarget.3324","article-title":"Hypomethylation and up-regulation of pd-1 in t cells by azacytidine in mds\/aml patients: A rationale for combined targeting of pd-1 and DNA methylation","volume":"6","author":"Orskov","year":"2015","journal-title":"Oncotarget"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1158\/2159-8290.CD-18-1356","article-title":"Immune checkpoint blockade enhances shared neoantigen-induced t-cell immunity directed against mutated calreticulin in myeloproliferative neoplasms","volume":"9","author":"Roudko","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_191","unstructured":"Bozkus, C.C., Finnigan, J.P., Mascarenhas, J., Hoffman, R., Bhardwaj, N., and Iancu-Rubin, C. (2017). Immune checkpoint blockade enhances mutated calreticulin-induced t cell immunity in myeloproliferative neoplasms. Blood, 130."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Prestipino, A., Emhardt, A.J., Aumann, K., O\u2019Sullivan, D., Gorantla, S.P., Duquesne, S., Melchinger, W., Braun, L., Vuckovic, S., and Boerries, M. (2018). Oncogenic jak2(v617f) causes pd-l1 expression, mediating immune escape in myeloproliferative neoplasms. Sci. Transl. Med., 10.","DOI":"10.1126\/scitranslmed.aam7729"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"Pd-l2 is a second ligand for pd-1 and inhibits t cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat. Immunol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood-2006-11-060087","article-title":"Interaction between b7-h1 and pd-1 determines initiation and reversal of t-cell anergy","volume":"110","author":"Tsushima","year":"2007","journal-title":"Blood"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit t cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1126\/scitranslmed.aav4810","article-title":"Clinical implications of tumor-intrinsic mechanisms regulating pd-l1","volume":"11","author":"Prestipino","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2008-07-168468","article-title":"Ctla4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation","volume":"113","author":"Bashey","year":"2009","journal-title":"Blood"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"7014","DOI":"10.1200\/JCO.2018.36.15_suppl.7014","article-title":"Nivolumab (nivo) maintenance (maint) in high-risk (hr) acute myeloid leukemia (aml) patients","volume":"36","author":"Kadia","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood-2018-99-120157","article-title":"Safety, efficacy, and biomarkers of response to azacitidine (aza) with nivolumab (nivo) and aza with nivo and ipilimumab (ipi) in relapsed\/refractory acute myeloid leukemia: A non-randomized, phase 2 study","volume":"132","author":"Daver","year":"2018","journal-title":"Blood"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(19)30114-0","article-title":"Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: A single-arm, phase 2 study","volume":"6","author":"Ravandi","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bcmd.2018.12.004","article-title":"Wt1 gene is overexpressed in myeloproliferative neoplasms, especially in myelofibrosis","volume":"75","author":"Cottin","year":"2019","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1089\/gtmb.2014.0281","article-title":"Does the level of wt1 expression predict the outcome in philadelphia-negative myeloproliferative neoplasms?","volume":"19","author":"Tasdemir","year":"2015","journal-title":"Genet. Test. Mol. Biomark."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/s41409-018-0383-2","article-title":"Post-transplant immunotherapy with wt1-specific ctls for high-risk acute myelogenous leukemia: A prospective clinical phase i\/ii trial","volume":"54","author":"Kim","year":"2019","journal-title":"Bone Marrow Transpl."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood.V84.9.3071.3071","article-title":"Wt1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia","volume":"84","author":"Inoue","year":"1994","journal-title":"Blood"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-017-0404-4","article-title":"High wt1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative pml-rara after anthracycline-based chemotherapy: A single-center cohort study","volume":"10","author":"Yoon","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting wt1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat. Med."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"174ra127","DOI":"10.1126\/scitranslmed.3004916","article-title":"Transferred wt1-reactive cd8+ t cells can mediate antileukemic activity and persist in post-transplant patients","volume":"5","author":"Chapuis","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood-2007-03-076844","article-title":"Graft-versus-leukemia effects associated with detectable wilms tumor-1 specific t lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia","volume":"110","author":"Rezvani","year":"2007","journal-title":"Blood"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/sj.leu.2403186","article-title":"Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with wt1 peptide in the absence of hematological or renal toxicity","volume":"18","author":"Mailander","year":"2004","journal-title":"Leukemia"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/6\/1559\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:43:20Z","timestamp":1760175800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/6\/1559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":209,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["cells9061559"],"URL":"https:\/\/doi.org\/10.3390\/cells9061559","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,26]]}}}